Company profile: Soley Therapeutics
1.1 - Company Overview
Company description
- Provider of AI-driven drug discovery solutions combining molecular and cellular response detection, including a proprietary platform that decodes cellular responses to predict cell fate, cellular sensing and anticipatory biology methods, and stress-modulating/tumor-targeting therapeutic discovery.
Products and services
- Cellular Sensing & Anticipatory Biology: Cell-based approach exploiting cells’ molecular sensing to predict outcomes, informing drug development via cellular response readouts
- Soley Evaluation Platform: Proprietary platform combining AI with decoding cellular responses to predict cell fate, accelerating drug discovery
- Stress Modulating / Tumor Targeting: Oncology-focused program interpreting cellular stress signals to discover therapeutics targeting tumors, guiding development of stress-responsive candidates
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Soley Therapeutics
Devax
HQ: United States
Website
- Description: Provider of medical devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Devax company profile →
Ablacon
HQ: United States
Website
- Description: Provider of AI-guided atrial fibrillation therapies, including the Ablamap System to localize and characterize functional mechanisms of AF for customized ablation; the Ablacath Mapping Catheter, used with Ablamap to identify and ablate sources outside the pulmonary veins; and the EGF Mapping System using electrographic flow mapping to detect and quantify patterns of electrical wavefront propagation in the atria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablacon company profile →
New Valve Technology
HQ: Switzerland
Website
- Description: Provider of medical devices for interventional cardiology and cardiac surgery, supporting minimally invasive treatment of valvular heart disease; develops, manufactures and markets these devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full New Valve Technology company profile →
Endologix
HQ: United States
Website
- Description: Provider of minimally invasive treatments for aortic disorders, offering the AFX2 Endovascular AAA System for abdominal aortic aneurysms with specific aneurysm morphology; the ALTO Abdominal Stent Graft System for infrarenal abdominal aortic aneurysms requiring specific vascular morphology; and the DETOUR System for percutaneous revascularization of symptomatic femoropopliteal lesions in patients suboptimal for surgical or alternative endovascular treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endologix company profile →
Cordis
HQ: United States
Website
- Description: Provider of less invasive treatments for vascular disease as a Johnson & Johnson company, and developer/manufacturer of stents, catheters, and guidewires. Offerings include SELUTION SLR Drug-Eluting Balloon for controlled, sustained sirolimus release; BRITE TIP Guiding Catheter; MYNX CONTROL Vascular Closure Device; RAIN Sheath Transradial thin-walled introducer; and RAILWAY Sheathless Access System.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cordis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Soley Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Soley Therapeutics
2.2 - Growth funds investing in similar companies to Soley Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Soley Therapeutics
4.2 - Public trading comparable groups for Soley Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →